FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: PeakClear all
ELIQUIS
apixaban
Peak
Bristol Myers Squibb
ORAL · TABLET, FOR SUSPENSION
deep vein thrombosis (DVT)which may lead to pulmonary embolism (PE)+11
2012
NDA
0/100
ELUCIREM
gadopiclenol
Peak
Guerbet
INTRAVENOUS · SOLUTION
older for use with magnetic resonance imaging (MRI) to detectvisualize lesions with abnormal vascularity in: the central nervous system (brain+8
2022
NDA
0/100
ELYXYB
celecoxib
Peak
ORAL · SOLUTION
migraine
2020
SMNDA
0/100
EMERPHED
ephedrine sulfate
Peak
INTRAVENOUS · SOLUTION
clinically important hypotension occurring in the setting of anesthesia
2020
NDA
0/100
EMPAVELI
pegcetacoplan
Peak
Apellis Pharmaceuticals
SUBCUTANEOUS · SOLUTION
older with C3 glomerulopathy (C3G)primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN)+1
2021
NDA
0/100
ENSTILAR
calcipotriene and betamethasone dipropionate
Peak
Leo Pharma
TOPICAL · AEROSOL, FOAM
psoriasis
2015
NDA
0/100
ENTRESTO
sacubitril and valsartan
Peak
Novartis
ORAL · TABLET
symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one yearolder+4
2015
SMNDA
0/100
EPANED
enalapril maleate
Peak
R-Pharm US
ORAL · SOLUTION
hypertensionto lower blood pressure in adults+14
2016
NDA
0/100
EPANED KIT
enalapril maleate
Peak
R-Pharm US
ORAL · FOR SOLUTION
hypertensionsymptomatic congestive heart failure+3
2013
NDA
0/100
EPANOVA
omega-3-carboxylic acids
Peak
AstraZeneca
ORAL · CAPSULE
2014
NDA
0/100
EPCLUSA
velpatasvir and sofosbuvir
Peak
Gilead Sciences
ORAL · TABLET
older with chronic HCV genotype 16 infection (): without cirrhosis+2
2016
SMNDA
0/100
EPCLUSA
velpatasvir and sofosbuvir
Peak
Gilead Sciences
ORAL · PELLETS
older with chronic HCV genotype 16 infection (): without cirrhosis+2
2021
SMNDA
0/100
EPHEDRINE SULFATE
ephedrine sulfate
Peak
Pfizer
INTRAVENOUS · SOLUTION
clinically important hypotension occurring in the setting of anesthesia
2020
NDA
0/100
EPIDIOLEX
cannabidiol
Peak
Jazz Pharmaceuticals
ORAL · SOLUTION
seizures associated with Lennox-Gastaut syndromeDravet syndrome+2
2018
NDA
0/100
EPRONTIA
topiramate
Peak
R-Pharm US
ORAL · SOLUTION
Epilepsymigraine
2021
NDA
0/100
EPSOLAY
benzoyl peroxide
Peak
TOPICAL · CREAM
inflammatory lesions of rosacea in adults
2022
NDA
0/100
ERLEADA
apalutamide
Peak
Johnson & Johnson
ORAL · TABLET
prostate cancer
2018
NDA
0/100
ERMEZA
levothyroxine sodium
Peak
Viatris (2)
ORAL · SOLUTION
hypothyroidism during the recovery phase of subacute thyroiditisincluding neonates+6
2022
NDA
0/100
ESBRIET
pirfenidone
Peak
Enterprise Therapeutics
ORAL · TABLET
idiopathic pulmonary fibrosis (IPF)
2017
NDA
0/100
ESBRIET
pirfenidone
Peak
Enterprise Therapeutics
ORAL · CAPSULE
2014
NDA
0/100
ESKATA
hydrogen peroxide
Peak
Aclaris Therapeutics
TOPICAL · SOLUTION
seborrheic keratoses
2017
NDA
0/100
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
esmolol hydrochloride
Peak
R-Pharm US
INTRAVENOUS · SOLUTION
noncompensatory sinus tachycardia wherethe physician's judgment+4
2016
NDA
0/100
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
esmolol hydrochloride
Peak
R-Pharm US
INTRAVENOUS · SOLUTION
noncompensatory sinus tachycardia wherethe physician's judgment+4
2016
NDA
0/100
ESOMEPRAZOLE MAGNESIUM
esomeprazole magnesium
Peak
Bridge Therapeutics
ORAL · TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
2020
NDA
0/100
← PreviousPage 32 of 55Next →